Skip to content
XPR
content.
Press releases
Video
Podcasts
Op-eds
Lists
Guest posts
Author:
Moderna, Inc.
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
June 18, 2026
Moderna to Host Investor Event – Science Day
June 17, 2026
Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
June 16, 2026
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
June 8, 2026
Moderna to Present at Upcoming Conference in June 2026
June 2, 2026